- Home
- ACAD vs RARE Comparison
ACAD vs RARE Comparison
Compare ACAD & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- RARE
- Stock Information
- Founded
- ACAD 1993
- RARE 2010
- Country
- ACAD United States
- RARE United States
- Employees
- ACAD N/A
- RARE N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- ACAD Health Care
- RARE Health Care
- Exchange
- ACAD Nasdaq
- RARE Nasdaq
- Market Cap
- ACAD 3.8B
- RARE 3.5B
- IPO Year
- ACAD 2004
- RARE 2014
- Fundamental
- Price
- ACAD $20.98
- RARE $29.31
- Analyst Decision
- ACAD Buy
- RARE Strong Buy
- Analyst Count
- ACAD 18
- RARE 15
- Target Price
- ACAD $27.71
- RARE $89.00
- AVG Volume (30 Days)
- ACAD 2.1M
- RARE 2.0M
- Earning Date
- ACAD 08-05-2025
- RARE 07-31-2025
- Dividend Yield
- ACAD N/A
- RARE N/A
- EPS Growth
- ACAD N/A
- RARE N/A
- EPS
- ACAD 1.37
- RARE N/A
- Revenue
- ACAD $996,283,000.00
- RARE $590,689,000.00
- Revenue This Year
- ACAD $13.39
- RARE $18.94
- Revenue Next Year
- ACAD $10.59
- RARE $28.93
- P/E Ratio
- ACAD $15.33
- RARE N/A
- Revenue Growth
- ACAD 22.42
- RARE 33.46
- 52 Week Low
- ACAD $13.40
- RARE $29.03
- 52 Week High
- ACAD $25.23
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- ACAD 45.70
- RARE 31.08
- Support Level
- ACAD $20.75
- RARE $29.06
- Resistance Level
- ACAD $23.09
- RARE $42.37
- Average True Range (ATR)
- ACAD 0.78
- RARE 1.79
- MACD
- ACAD -0.20
- RARE -0.70
- Stochastic Oscillator
- ACAD 9.83
- RARE 5.07
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.